Skip to main content

Table 3 Outcomes of thiopurine therapy in patients with or without NUDT15 polymorphisms

From: TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

  NUDT15 (mutated)
(N = 13)
n (%)/ Median (IQR)
Wild Genotype
(N = 102)
n (%)/ Median (IQR)
p value
Hemoglobin (g/dL) at end of follow up 12 (2.8) 11.05 (3.4) 0.289
Total leucocyte count (× 106/L) at end of follow up 3600 (1700) 5700 (3575) 0.006
Platelet count (× 106/L) at end of follow up 214,000 (109,000) 254,000 (132,500) 0.289
Duration of thiopurine use (months) 11 (9) 8 (15.25) 0.168
Max tolerated azathioprine equivalent dose (mg/d) 50 (50) 100 (25) 0.253
Leukopenia 7 (53.8%) 25 (24.5%) 0.026
Idiosyncratic reaction 0 6 (5.9%) 1.000
Treatment interruption 7 (53.8%) 29 (28.4%) 0.063
  1. Bold means statistically significant